Sqz Biotechnologies Company · OTC:SQZB
Sqz Biotechnologies — Investor Presentation (June 2021)
29 slides from Sqz Biotechnologies's investor presentation, Jun 4, 2021
Slide 1: SQZ Biotech - June 2021
Exhibit 99.2 SQZBIOTECH Gana June 2021
Slide 2: Forward-looking statements
2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements rel
Slide 3: Demonstrated Safety & Manufacturing: Could Open Broader Cell Therapy Universe
3 Demonstrated Safety & Manufacturing: Could Open Broader Cell Therapy Universe Cell Squeeze® Technology Universe of Possible Cell Therapies Electroporation Viral transduction Efficient process Flexible across cell types and cargos Fast and reliable manufacturing Broadly applicable across disease ar
Slide 4: Unique Technology Enables Differentiated Capabilities
4 Unique Technology Enables Differentiated Capabilities Broad Capabilities Applicable to diverse cell types Robust across material classes Preservation of cell function Rapid Manufacturing (>10B cells/min)
Slide 5: Speed and Reliability of SQZ Autologous Cell Therapy Potentially Rivals Allogeneic
5 Speed and Reliability of SQZ™ Autologous Cell Therapy Potentially Rivals Allogeneic TALENT AND CULTURE 1 Allogene ASCO 2020 2 Median 5 days from enrollment to lymphodepletion and 5-7 days for lymphodepletion regimen. ALLO-501 ALPHA trial 3 Kymriah (tisagenlecleucel) [package insert], Yescarta (axi
Slide 6: Point-of-Care Vision: Potential to Transform Cell Therapy Through Onsite Manufacturing
6 Prototype Expected in 2021 Point-of-Care Vision: Potential to Transform Cell Therapy Through Onsite Manufacturing TALENT AND CULTURE Reduced transportation and logistics costs Potential for same-day treatment No clean room Integrated single system operated by hospital staff On-site production
Slide 7: Directing Immune System to Drive Antigen Specific Immunity
7 Directing Immune System to Drive Antigen Specific Immunity Oncology Autoimmune Diseases Infectious Diseases and beyond Aiming to redirect, reinforce and reengage immune system through antigen-specific cell therapies
Slide 8: Upcoming Milestones Across Pipeline
ONCOLOGY 8 Upcoming Milestones Across Pipeline PLATFORM INDICATION Other Solid Tumors KRAS mut Solid Tumors H&N, Cervical, Anal H&N, Cervical, Anal PRE-CLINICAL PHASE 1 Monotherapy biomarker data (ASCO) Combination data HBV IND submission Monotherapy data KRAS IND submission IND-enabling studies UPC
Slide 9: SQZ Approach Unlocking the Full Potential of Cell Therapies
9 SQZ™ Approach Unlocking the Full Potential of Cell Therapies Oncology Autoimmune Diseases Infectious Diseases and beyond Using directed immunity to bring cell therapies to disease areas with significant unmet need
Slide 10: Potential to Address Broad Range of Cancers
10 Potential to Address Broad Range of Cancers Estimated 39,000 cases/yr in US Primarily HNSCC, Cervical, Anal Platforms Designed for Rapid Expansion into Additional Indications Initial Trials in HPV+ Tumors Could Unlock Additional Cancers Worldwide >630,000 HPV+ diagnoses annually HPV+ Tumors Other
Slide 11: SQZ cell-based therapeutic vaccine approaches aim to drive robust patient CD8 T cell activity
11 SQZ™ cell-based therapeutic vaccine approaches aim to drive robust patient CD8 T cell activity Development and manufacturing synergies potentially enable rapid clinical translation Engineering Antigen Presentation for Powerful CD8 Activation CD8 T Cell Infiltration as a Prognostic Indicator in So
Slide 12: SQZ Approach Unlocking the Full Potential of Cell Therapies: Oncology
12 SQZ™ Approach Unlocking the Full Potential of Cell Therapies Oncology Using directed immunity to bring cell therapies to disease areas with significant unmet need Autoimmune Diseases Infectious Diseases and beyond
Slide 13: Powerful CD8 Activation with Robust MHC-I Antigen Presentation
13 Powerful CD8 Activation with Robust MHC-I Antigen Presentation Squeezed Antigen MHC-I = CD8 T Cell Activation SQZTM APC Process Dramatically improved potential for efficacy vs Cross-Presentation Other vaccines, including the only approved cancer vaccine (Dendreon) use Cross-Presentation SQZTM tec
Slide 14: Flexible APC Candidate Trial Design
14 Flexible APC Candidate Trial Design | Monotherapy & Combination with ICIs Potential for earlier lines of therapy Earlier lines of therapy Later lines of therapy 0.5M cells per kg 2.5M cells per kg 5M cells per kg (DP) Cohort 1 Cohort 2 Monotherapy Enrollment Complete Open for Enrollment Cohort 3a
Slide 15: SQZ APCs Demonstrated Safety and Reliable Manufacturing
15 SQZ™ APCs Demonstrated Safety and Reliable Manufacturing End-to-End Process Time Viability Manufacturing: Robust, consistent production in <24hrs All manufactured patient APCs induced IFN-γ secretion by T cells No subject met pre-specified DLT criteria No related Grade ≥3 SAEs reported: Grade 2 (
Slide 16: Encouraging Increase in Immune Activity in Certain Patients
16 Encouraging Increase in Immune Activity in Certain Patients 65-year-old woman – cervical cancer 3.5 years after diagnosis following treatment with (1) cisplatin/paclitaxel/ bevacizumab [BOR=CR] and (2) Pembrolizumab [BOR=PD] Low tumor burden, ECOG=0, RMH=1 On treatment for 10+ months, BOR=SD 2-fo
Slide 17: Next Step: Combinations - Potential Synergies with Other I/O Compounds
17 Next Step: Combinations - Potential Synergies with Other I/O Compounds SQZ APCs aim to elicit tumor-specific CD8 T cells Other I/O compounds could synergistically enhance an antigen-specific response Presented at SITC 2020 in SQZ Poster and Roche Oral Presentation SQZTM APCs drive tumor-specific
Slide 18: SQZ Approach Unlocking the Full Potential of Cell Therapies: Oncology
18 SQZ™ Approach Unlocking the Full Potential of Cell Therapies Oncology Using directed immunity to bring cell therapies to disease areas with significant unmet need Autoimmune Diseases Infectious Diseases and beyond
Slide 19: Enhancing with Combination-like Functionality
Enhancing with Combination-like Functionality Key Features/Benefits: Multiple mRNA as cargo Further amplify MHC-I for more powerful CD8 activation Addition of co-stimulatory factors and cytokines: membrane-bound IL-2, IL-12 and CD86 Potential for combination functionality in single cell therapy Coul
Slide 20: eAPC IND Planned for Q4 2021
eAPC IND Planned for Q4 2021 CD86 1 2 3 Signals CD8 T Cell SQZ eAPC IL-2 IL-12 TCR MHC-I Potential to Enhance Responses and Expand Addressable Patient Population Potential to eliminate HLA restrictions and expand addressable patient population 20 TM
Slide 21: SQZ Approach Unlocking the Full Potential of Cell Therapies: Oncology
21 SQZ™ Approach Unlocking the Full Potential of Cell Therapies Oncology Using directed immunity to bring cell therapies to disease areas with significant unmet need Autoimmune Diseases Infectious Diseases and beyond
Slide 22: Creating Antigen Carriers from RBCs to Direct Immune Response
Creating Antigen Carriers from RBCs to Direct Immune Response Antigen Carriers (ACs) generated by squeezing RBCs deliver antigen to guide a specific immune response ACs are cleared by the same process as aged RBCs in vivo Professional APCs in lymphoid organs are primarily responsible for RBC clearan
Slide 23: SQZ AACs Demonstrated Robust Activation in Preclinical Studies
23 SQZ™ AACs Demonstrated Robust Activation in Preclinical Studies Antigen + Activating Adjuvant T cell activation Activation Lymphoid Organ SQZ™ AACs Data in HPV Tumor Model As presented at SITC 2020
Slide 24: SQZ-AAC-HPV Phase Clinical Trial Across HPV+ Tumor Types
24 SQZ-AAC-HPV Phase 1 Clinical Trial Across HPV+ Tumor Types Potential for earlier lines of therapy Earlier lines of therapy Later lines of therapy 50 M AACs/kg Dose determined by Cohort 1 observations Additional Cohorts Cohort 1 Cohort 2 Monotherapy Multiple I/O Combo Cohorts Combination Therapy E
Slide 25: SQZ Approach Unlocking the Full Potential of Cell Therapies: Autoimmune Diseases
25 SQZ™ Approach Unlocking the Full Potential of Cell Therapies Oncology Autoimmune Diseases Using directed immunity to bring cell therapies to disease areas with significant unmet need Infectious Diseases and beyond
Slide 26: Directing Tolerogenic Immune Response
Directing Tolerogenic Immune Response SQZ™ Tolerizing Antigen Carriers (SQZ TACs) Leveraging antigen carriers from RBCs loaded with antigen only (no adjuvant) tolerize the immune response to that antigen Antigen Antigen + Activating Adjuvant SQZ Cargo T cell activation Activation Tolerization SQZ AA
Slide 27: Prevented Onset of T1D in Multiple Models and Showed Decreased Insulitis
27 Prevented Onset of T1D in Multiple Models and Showed Decreased Insulitis SQZ TACs Demonstrate Disease Altering Benefit in T1D Model Antigen-Specific Treg Increase in Pancreas
Slide 28: Unlocking the Full Potential of Cell Therapies
28 Unlocking the Full Potential of Cell Therapies Oncology Autoimmune Diseases Infectious Diseases and beyond Using directed immunity to bring cell therapies to disease areas with significant unmet need
Slide 29: Demonstrated Safety & Manufacturing: Could Open Broader Cell Therapy Universe
29 Demonstrated Safety & Manufacturing: Could Open Broader Cell Therapy Universe Cell Squeeze® Technology Versatile technology could enable rapid portfolio growth Demonstrated safety and manufacturing with lead program in clinic Validating Roche collaboration for SQZ™ APCs in oncology Multiple cell
SQZ Biotechnologies — Investor Presentation (June 2021) on 6ix